Clinical observation of oxcarbazepine suspension monotherapy for 2 to 4-year-old patients newly diagnosed as partial epilepsy / 中华神经科杂志

ABSTRACT

Objective To investigate the efficacy and safety of oxcarbazepine (OXC) suspension for treating the 2 to 4 years old patients newly diagnosed as partial epilepsy.Methods A total of 62 patients between 2 to 4 years old diagnosed as partial epilepsy,selected from the outpatients of the pediatric neurology in the hospital from October 2009 to March 2011,were randomly divided into the experimental group of 32 patients and the control group of 30 patients.Experimental groupOXC suspension,the initial dose was 8-10 mg· kg-1 d-1,orally taking 2 times every day,increasing the dose by 10 mg · kg-1 d 1 once every 7 days to the complete control of the seizure,the target dose was 20-40 mg· kg-1 · d-1 Control grouporal administration of carbamazepine (CBZ) group,the initial dose was 5 mg· kg 1 · d-1,increasing the dose once every 5-7 days up to 10-15 mg · kg-1 · d-1,if necessary,the dose could be 20 mg · kg 1 d-1 to maintain.The observation period was 26 weeks.Results The rate of valid cases in OXC group after 13 weeks and 26 weeks were both 78.1％ (25/32),and the rate of non-attack cases were 53.l％ (17/32) and 50.0％ (16/32),respectively; the rate of valid cases in CBZ group after 13 weeks and 26 weeks were 76.7％ (23/30) and 70.0％ (21/30),respectively,and the rate of non-attack cases were 50.0％ (15/30) and 40.0％ (12/30) (x2 =0.022,0.004 ; P =0.883,0.947 respectively.).In the 26th week,the quit rate of OXC group was 6.2％,while the quit rate of CBZ group was 13.4％.The rates of adverse reactions of OXC and CBZ were 15.6％ and 26.7％,respectively,with no significant difference.Conclusion OXC suspension monotherapy for 2 to 4 years old patients with partial epilepsy was significant effective,and no significant difference when compared with carbamazepine group.The rate of the adverse reactions in the OXC group was relatively fewer,and the extent was slight.